Advanced search
Publication Cover
Journal of Asthma and Allergy Volume 14, 2021 - Issue
Submit an article Journal homepage
110
Views
2
CrossRef citations to date
0
Altmetric
Case Series

Real-World Experience on Omalizumab Treatment for Patients with Normocomplementemic Urticarial Vasculitis

Taoming LiuDepartment of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
,
Juan BaiDepartment of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
,
Shuni YingDepartment of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
,
Sheng LiDepartment of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-4641-7907
ORCID Icon,
Yunlei PanDepartment of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
,
Deren FangDepartment of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
,
Jianjun QiaoDepartment of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of ChinaCorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0003-3386-297X
ORCID Icon &
Hong FangDepartment of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-4940-9662
ORCID Icon show all
Pages 433-437 | Published online: 23 Apr 2021

References

  • Venzor J, Lee WL, Huston DP. Urticarial vasculitis. Clin Rev Allergy Immunol. 2002;23(2):201–216. doi:10.1385/criai:23:2:201
  • Tosoni C, Lodi-Rizzini F, Cinquini M, et al. A reassessment of diagnostic criteria and treatment of idiopathic urticarial vasculitis: a retrospective study of 47 patients. Clin Exp Dermatol. 2009;34(2):166–170. doi:10.1111/j.1365-2230.2008.02891.x
  • Kolkhir P, Grakhova M, Bonnekoh H, Krause K, Maurer M. Treatment of urticarial vasculitis: a systematic review. J Allergy Clin Immunol. 2019;143(2):458–466. doi:10.1016/j.jaci.2018.09.007
  • Lee JS, Loh TH, Seow SC, Tan SH. Prolonged urticaria with purpura: the spectrum of clinical and histopathologic features in a prospective series of 22 patients exhibiting the clinical features of urticarial vasculitis. J Am Acad Dermatol. 2007;56(6):994–1005. doi:10.1016/j.jaad.2006.10.962
  • Navarro-Navarro I, Jiménez-Gallo D, Villegas-Romero I, Linares-Barrios M. Use of omalizumab in the treatment of hypocomplementemic urticarial vasculitis. Dermatol Ther. 2020;33(2):e13237. doi:10.1111/dth.13237
  • Pérez Codesido S, Rosado Ingelmo A, Gómez de la Fuente E, García García E, Privitera Torres M, Tejedor Alonso MA. Successful treatment of hypocomplementemic urticarial vasculitis with omalizumab: a case report. J Investig Allergol Clin Immunol. 2020;30(3):211–212. doi:10.18176/jiaci.0486
  • Aurich S, Simon JC, Treudler R. Omalizumab does not improve skin lesions in a patient with hypocomplementemic urticarial vasculitis syndrome. J Eur Acad Dermatol Venereol. 2017;31(9):e395–e397. doi:10.1111/jdv.14202
  • Nucera E, Basta F, Buonomo A, et al. A case of hypocomplementemic urticarial vasculitis syndrome successfully treated with omalizumab. J Investig Allergol Clin Immunol. 2017;27(6):382–384. doi:10.18176/jiaci.0191
  • Rattananukrom T, Svetvilas P, Chanprapaph K. Successful treatment of normocomplementemic urticarial vasculitis with omalizumab: a report of three cases and literature review. Asian Pac J Allergy Immunol. 2020;38(4):286–289. doi:10.12932/ap-050918-0402
  • Ito T, Maeda T, Egusa C, et al. Effectiveness of omalizumab in two cases of normocomplementemic urticarial vasculitis due to perivascular mast cell infiltration. Allergol Int. 2020. doi:10.1016/j.alit.2020.09.012
  • de Brito M, Huebner G, Murrell D, Bullpitt P, Hartmann K. Normocomplementaemic urticarial vasculitis: effective treatment with omalizumab. Clin Transl Allergy. 2018;8:37. doi:10.1186/s13601-018-0222-y
  • Chen YD, Krause K, Tu P, Zhao ZT, Maurer M. Response of omalizumab in normocomplementemic urticarial vasculitis. J Allergy Clin Immunol Pract. 2020;8(6):2114–2117.e2. doi:10.1016/j.jaip.2020.02.024
  • Raphael MJ, Gyawali B, Booth CM. Real-world evidence and regulatory drug approval. Nat Rev Clin Oncol. 2020;17(5):271–272. doi:10.1038/s41571-020-0345-7
  • Krause K, Mahamed A, Weller K, Metz M, Zuberbier T, Maurer M. Efficacy and safety of canakinumab in urticarial vasculitis: an open-label study. J Allergy Clin Immunol. 2013;132(3):751–754.e5. doi:10.1016/j.jaci.2013.04.008
  • Lennox RD, Leahy MJ. Validation of the Dermatology Life Quality Index as an outcome measure for urticaria-related quality of life. Ann Allergy Asthma Immunol. 2004;93(2):142–146. doi:10.1016/s1081-1206(10)61466-4
  • Młynek A, Zalewska-Janowska A, Martus P, Staubach P, Zuberbier T, Maurer M. How to assess disease activity in patients with chronic urticaria? Allergy. 2008;63(6):777–780. doi:10.1111/j.1398-9995.2008.01726.x
  • Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368(10):924–935. doi:10.1056/NEJMoa1215372
  • Fueyo-Casado A, Campos-Muñoz L, González-Guerra E, Pedraz-Muñoz J, Cortés-Toro JA, López-Bran E. Effectiveness of omalizumab in a case of urticarial vasculitis. Clin Exp Dermatol. 2017;42(4):403–405. doi:10.1111/ced.13076
  • Cherrez-Ojeda I, Vanegas E, Felix M, Mata VL, Cherrez A. Patient-reported outcomes in urticarial vasculitis treated with omalizumab: case report. BMC Dermatol. 2018;18(1):8. doi:10.1186/s12895-018-0077-x
  • Ghazanfar MN, Thomsen SF. Omalizumab for urticarial vasculitis: case report and review of the literature. Case Rep Dermatol Med. 2015;2015:576893. doi:10.1155/2015/576893
  • Davis MDP, van der Hilst JCH. Mimickers of urticaria: urticarial vasculitis and autoinflammatory diseases. J Allergy Clin Immunol Pract. 2018;6(4):1162–1170. doi:10.1016/j.jaip.2018.05.006
  • Bettuzzi T, Deroux A, Jachiet M, et al. Dramatic but suspensive effect of interleukin-1 inhibitors for persistent urticarial vasculitis: a French multicentre retrospective study. Ann Rheum Dis. 2019;78(10):1446–1448. doi:10.1136/annrheumdis-2019-215605

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.